#HIV
Clinical Trial Update: We’re excited to announce that American Gene has hit two major benchmarks in our Phase 1
#genetherapy
trial, bringing us closer to a potential cure for HIV. We expect to submit the final Phase 1 trial report to the FDA in 2023.
Exciting HIV Clinical Trial Update: American Gene has reached a turning point in our
#HIV
clinical trial! We’re withdrawing participants from their antiretroviral drugs, which will determine if our
#genetherapy
treatment could potentially cure HIV.
One year after receiving the green light from the FDA to initiate a Phase I study of an
#HIV
gene &
#celltherapy
, AGT has infused the first patient. AGT103-T is designed as a cure for the disease that has impacted lives globally since the 1980s. Read more:
“One patient can be lucky. Two can be very lucky. Three is a trend...” -
@JeffreyGalvin
. The third patient in our human trials for AGT103-T has been treated with no adverse events recorded, allowing the clinical trial to accelerate greatly. Learn more:
“Laboratory studies confirmed substantial increases in virus-specific T cells consistent with improved immunity against HIV in all participants.” Read the latest exciting update from our
#HIV
Cure Program now:
Our
#HIV
Cure Program is advancing at full speed as the DSMB found no serious, adverse events in the third patient treated with AGT103-T. With this development, the DSMB will now meet quarterly, with no check-ins needed between patients. Learn more:
“If this works, they will be permanently immune from HIV.” -CEO
@JeffreyGalvin
. We recently celebrated the successful infusion of 2 patients in our Phase 1 human trial. As await the next safety data, we hold hope that we are close to a cure. Read more:
Our
#HIV
Cure Program continues with great progress as the IRB gives us the green light to proceed with analytic treatment interruption. As we prepare to withdraw participants from ARTs, we may be close to demonstrating a functional cure for HIV. Read now:
As our Phase 1 clinical trial for an
#HIV
cure continues, data from the first three patients showing initial blood markers of efficacy indicate that we are on the right track. Read the latest news:
Our
#clinicaltrial
for a potential
#HIV
cure continues with much optimism as two more patients demonstrate critical markers of the AGT103-T therapy. Read the press release now:
“It's believed the immune response triggered would be enough to fight HIV, without current antiviral treatments available.” Our
#clinicaltrial
for an
#HIV
cure remains on track as we enter this new year, and we can't wait for the next milestone. Read now:
“We all have something to be excited about.” The first patient to receive
#AGT103T
suffered no adverse effects from treatment, giving us hope that we can soon contribute to ending the ongoing
#HIV
epidemic. Read more here:
On the heels of our first patient infusion, we are happy to announce that the second patient in our
#HIV
cure program has been treated with AGT103-T and the DSMB found no adverse reactions, allowing us to continue our trial without modification. Read more:
We’ve reached a critical step in our mission to cure
#HIV
with
#genetherapy
: withdrawing participants from their ARTs. We’re optimistic but it'll take months to evaluate the data from all 7 participants. Follow new developments on our newsletter & social.
There are approximately 38 million people globally with
#HIV
. Although a cure is not available yet, our first participant infusion of the AGT103-T product brings hope to the advancement of cure research. Read
@BioBuzzMaryland
's article
AGT is moving closer to its goal of allowing people with
#HIV
to return to a normal life without
#ART
as new data shows all five patients display critical markers of AGT103-T. Learn more:
This is an amazing moment in our history. We'll begin the Phase 1 human trial of our
#HIV
therapy! We know a lot of people have been waiting for this for years. Join us in celebrating! Leave a comment and share the news.
#genetherapy
#celltherapy
#biotech
“We believe it is possible for a one-and-done therapy to make a person living with HIV permanently immune to HIV, and this recent data increases our optimism that we are on track.” -
@JeffreyGalvin
. Read the latest news on our
#HIV
cure
#clinicaltrial
:
At this stage in our
#clinicaltrial
for AGT103-T, a potential
#genetherapy
cure for
#HIV
, the IRB has given us the green light to withdraw patients from their ARTs. Follow our HIV Cure Countdown and be the first to know our next update:
#ClinicalTrialsDay
On HIV Vaccine Awareness Day, we laud research efforts to prevent the spread of HIV with a vaccine. At AGT, we’re working on a
#genetherapy
cure for the 38 million people globally living with
#HIV
. These continued efforts bring hope that we'll see the end of
#HIV
in our lifetime.
Our Phase I clinical trial for an
#HIV
cure recently hit a milestone as we infused our first patient. We are optimistic about the future of this gene therapy & the possibilities it holds! Read more on
@BioBuzzMaryland
:
About 38 million people globally live with HIV, but is HIV treatable? We are currently in
#clinical
trials for a cell therapy that can potentially provide the long-awaited cure for HIV and eliminate antiretroviral dependency. Read our
#research
:
“Early data in three patients shows their altered cells are not getting infected, maintaining characteristics that show they're ready to fight HIV.” Thank you
@justinhintontv
for continuing to share the milestones in our
#HIV
Cure Program. Read the news:
12+ years of research has yielded a new approach to fighting
#HIV
, which has attracted leading scientists, doctors, and
#community
members engaged in cure research. Learn more about our program in a Phase 1 trial
#CellTherapy
#GeneTherapy
#croi2021
We're thankful
#AGT103T
is proving safe in humans. The DSMB reviewed AGT's safety data in our
#clinicaltrial
for a potential cure for
#HIV
; they unanimously voted to continue the study without modification. We'll celebrate this milestone together tomorrow & we'll never give up.
Exciting News! American Gene's Phase 1
#HIV
clinical trial data was published in the scientific journal “Frontiers in Medicine”: The data shows we’ve met the trial’s primary and secondary goals. Follow for future developments.
Our
#HIV
Cure Program has achieved new milestones as the initial data from the first three participants demonstrated blood markers of efficacy, bringing hope that AGT103-T may be able to create an immune response against HIV without
#ART
. Read now:
In the case of AGT103-T, T cells are first taken from a patient and “trained” to detect certain HIV-specific proteins, gearing them up to attack
#HIV
. The cells are then grown to large numbers in the lab and equipped with new “software." Read more
“It's believed the immune response triggered would be enough to fight HIV, without current antiviral treatments available.” Our
#clinicaltrial
for an
#HIV
cure remains on track as we enter the new year! Read the latest news:
We are grateful for the advancements in
#science
and
#medicine
that have resulted in treatments for
#HIV
. As our HIV Cure Program progresses, we believe we are moving closer to a future where cures, not just treatments, exist for the millions affected.
#WeNeedACure
“Early data in three patients shows their altered cells are not getting infected, maintaining characteristics that show they're ready to fight HIV.” Read the latest news from our
#clinical
trial for an
#HIV
cure now on
@7NewsDC
:
As our Phase 1 clinical trial for an
#HIV
cure continues, the efficacy data may come sooner than you think. CEO
@JeffreyGalvin
spoke to
@WashBlade
about the current trial progress after the DSMB voted to continue the trial without modification. Read now:
While the battle against
#HIV
has not yet been won, AGT advances forward with a viable
#strategy
to strengthen the immune system’s ability to identify and disable the virus. If successful, AGT’s therapy may be a functional
#cure
for HIV. Read more
#science
About 38 million people globally live with HIV. Is an
#HIV
cure achievable? We are in a clinical trial for a cell therapy that can potentially provide a long-awaited functional cure and eliminate antiretroviral dependency. Read our
#research
:
With a green light from the FDA, our
#HIV
cure program clinical trial has started. We're pre-revenue & rely solely on investments to fund research. On
#WorldAIDSDay
, you can help our Phase 1 trial with just one purchase!
Join the fight & rock AGT swag ➡️
In the case of AGT103-T, T cells are first taken from a patient and “trained” to detect certain HIV-specific proteins, gearing them up to attack
#HIV
. The cells are then grown to large numbers in the lab and equipped with new “software." Read more
The third patient in our human trials for the
#HIV
cure program has been infused, and AGT103-T is continuing to prove safe in participants. Our trial is advancing as the DSMB eliminates the requirement of reviews between each participant. Read now:
.
@BioBuzzMaryland
reports that one year after receiving the green light from the FDA to initiate a Phase 1 study of an
#HIV
cell therapy,
@AmericanGene
has infused its first patient. Read their article:
We recently celebrated another milestone in our Phase 1 RePAIR
#clinicaltrial
of our
#HIV
cure program
#AGT103T
.
Thank you to our AGT friends & family for your support and belief in our team. We can’t wait to celebrate the next milestone with you!
AGT's purpose is to help those who have suffered throughout the world, who have yet to see a vaccine or a cure. This company intends to change that outcome for the better. AGT is modifying cells in 3 ways to stop, turn off, and kill the virus. Read more:
This year marked 40 years since the first incidence of
#HIV
in the United States. As we edge closer to the potential cure for HIV, read the history of HIV Cure Research on our blog:
2019: AGT Submits Investigational New Drug Application to the FDA for
#HIV
Cure Program
2020: FDA Allows Human Trial; First Participants Enrolled
2021: First Patient Receives AGT103-T drug; USMB reviews safety data & unanimously votes to continue study.
For over 40 years,
#HIV
has been managed thanks to advancements in
#science
and
#medicine
. American Gene is committed to pursuing a cure in hopes that one day, we will see the end of HIV in our lifetime.
#WeNeedACure
Exciting News: The
#ATI
has already highlighted impressive viral suppression and immunological data. We are not at the finish line yet, but the data from our Phase 1
#HIV
#clinicaltrial
is promising. Follow
@Addimmune
for updates on
#AGT103
-T, here:
Many individuals have been affected by or know someone who has
#HIV
. The question today is, can HIV be cured? Read the
#history
of HIV treatment moving toward a cure.
American Gene Technologies is devoted to ending
#HIV
. Every day, our HIV Cure Program makes great progress that brings us one step closer to a cure. Learn more:
Data and Safety Monitoring Board
#DSMB
voted unanimously to continue AGT’s
#HIV
cure program human trial without modification after
#safety
analysis of the participant’s data revealed no adverse effects from the treatment
#AGT103T
. Read more:
“The main thing I don't want to do is overpromise, but at the same time, I'm getting more and more optimistic every day.” -CEO
@JeffreyGalvin
. Read the latest news in our
#HIV
Cure Program's
#clinicaltrial
:
AGT's purpose is to help those who have suffered throughout the world, who have yet to see a cure. This company intends to change that outcome for the better. AGT is modifying cells in 3 ways to stop, turn off, and kill the virus.
Read:
#HIV
As the IRB gives AGT the green light to proceed with analytic treatment interruption at this stage in our
#HIV
Cure Program, we remain optimistic that we are moving closer to demonstrating a functional cure for HIV. Read the latest update now:
As our work week comes to a close, we are reminded that we dedicate our days to accelerating
#cure
research that can improve the lives of millions suffering from diseases like
#HIV
. We are in this together.
#WeNeedACure
In the case of AGT-103-T, T cells are first taken from a patient and “trained” to detect certain HIV-specific proteins, gearing them up to attack
#HIV
. The cells are then grown too large numbers in the lab and equipped with new “software." Read research:
What if there was a cure for
#HIV
? An
#HIVcure
would free people from relying on antiretroviral therapy and give them permanent immunity with no chance of being diagnosed again. Here’s why we should focus on curing diseases like HIV, not just treating them:
Withdrawing participants from their antiretroviral medications is a pivotal development in our
#HIV
#genetherapy
clinical trial. Learn about the analytic treatment interruption (ATI) and how it may determine whether AGT103-T can potentially cure HIV.
We celebrated another amazing milestone in our Phase 1 trial with our AGT family to recognize the hard work of our
#team
. The Data and Safety Monitoring Board (DSMB) voted unanimously to continue our
#HIV
cure program without modification!
Learn more:
As we continue reaching incredible milestones in our
#HIV
Cure Program, check out our HIV Cure Countdown! Don't miss out on the latest clinical trial updates and sign up to receive the latest news!
“With no serious adverse effects observed in the third participant, we’re seeing a verifiable trend in the data that gives reasonable confidence that the treatment has low risk of adverse events.” -CEO
@JeffreyGalvin
. Read the full press release now:
We're grateful for the continued advancements in
#science
and
#medicine
that have resulted in treatments for
#HIV
. Our
#HIVCureProgram
gives us hope that one day, we'll have a cure, not just a treatment, for those in need. Learn more:
#WeNeedACure
The arc of
#HIV
history has been developing over the last 40 years. While there have been attempts to cure the disease in the past,
#genetherapy
proves promising as the next step to ending the epidemic. Read the full history of HIV on our blog:
“We all have something to be excited about in terms of the probability that we will see the end of HIV in our lifetime.” -CEO
@jeffreygalvin
. Watch the video from our celebration of the first safety data in our
#HIV
Cure Program now:
We launched The Cure Chronicles to highlight the incredible achievements of the
#HIV
community and the breakthroughs that have been made in the effort to end the epidemic. Catch up on all episodes now:
#TheCureChronicles
Many individuals have been affected by or know someone who has
#HIV
. An estimated 1.2 million Americans are infected with the virus. The question today is, can HIV be cured? Read the
#history
of HIV treatment moving toward a cure:
We must advance research to durably suppress
#HIV
in a way that offers disease control without dependence on lifelong antiretroviral treatments. Our products approaching or already in clinical trials hold great promise to do this.
Read more
#science
The Berlin Patient’s functional
#cure
gave hope that there was a way to eradicate
#HIV
and eliminate the need for ongoing anti-retroviral therapy. Learn more here:
Our
#clinicaltrial
reached new milestones as the first three patients infused achieved engraftment & avoided rejection of the infused cells. Patient samples also demonstrated an active
#HIV
-specific response when challenged. Read the full press release:
2021 marked 40 years since the first incidence of
#HIV
in the United States. As we edge closer to the potential cure for HIV, read the history of HIV Cure Research on our blog:
#WeNeedACure
If you care about
#HIV
cure research, you must watch the video interview of
@jeffreygalvin
&
@justinhintontv
explaining our progress and achieving this major milestone of infusing our first patient with what we hope will be an HIV cure. Watch (mid-page):
We’re excited to announce the launch of The Cure Chronicles - our new video series highlighting the incredible work being done by people living with
#HIV
, researchers, advocates, and more to end the HIV epidemic. Watch now:
#TheCureChronicles
At AGT, it is our mission to leverage the power of gene &
#celltherapy
to reduce human suffering or early death from serious human diseases. We need cures, not just treatments, for the millions suffering from diseases like
#HIV
. Join us in our mission.
#WeNeedACure
“We all can be doing more to ensure this disease doesn’t ravage another generation,” says
@raviperry
. Our
#HIV
Cure Program is in human trials with the hope that it can positively impact patients’ lives soon.
Read
@wusa9
@LorenzoHall
's report:
Today is the day! Join us virtually as we share data from our Phase I
#HIV
#clinicaltrial
and the next steps for Phase II. We’ll also be announcing business developments to allow us to solely focus on the
#HIVCure
program. .
We are committed to
#HIV
cure research. Watch to learn more about our cell and gene therapy program, currently in human trials in DC and Baltimore, Maryland:
#heathcare
The arc of
#HIV
history has been developing over the last 40 years. While there have been many attempts to cure the disease in the past,
#genetherapy
proves promising as the next step to ending the epidemic. Read now:
The Berlin Patient’s functional
#cure
gave hope that there was a way to eradicate
#HIV
and eliminate the need for ongoing anti-retroviral therapy. Learn more here:
Our
#HIV
Cure Program is accelerating greatly as the DSMB found no serious adverse events in the first three patients treated with AGT103-T. Check out the video from our celebration of the first safety data!
HIV/AIDS has left a detrimental mark on history. Supporting research is essential to end the epidemic. Help accelerate
#HIV
cure research by purchasing AGT swag this holiday & 100% of your contribution will go to patient clinical care in our Phase 1 study:
“After working with HIV/AIDS patients for 40 years, I am cautiously optimistic that a major turning point is near after looking at AGT’s data and process.” -Dr. Marcus Conant. Read the full press release:
There are two different kinds of
#HIV
#cures
#scientists
can work toward developing.
A
#SterilizingCure
would completely eliminate replication-competent proviruses in the body. A
#FunctionalCure
would enable long-term control of HIV replication without continuous treatment.
It is incredible news to hear an
#HIV
injection from
@ViivHC
can now reduce
#PrEP
intervals to once every 2 months. We hope that one day, a one-and-done cure will be available.
#WeNeedACure
This year marked 40 years since the first incidence of
#HIV
in the United States. As we edge closer to the potential cure for HIV, read the history of HIV Cure Research from discovery to treatment on our blog:
“We believe it is possible for a one-and-done therapy to make a person living with HIV permanently immune to HIV, and this recent data increases our optimism that we are on track.” -
@JeffreyGalvin
. Read the latest news on our
#HIV
cure
#clinicaltrial
:
2021 will be a huge year for gene therapy. We've made progress on our AGT103-T
#HIV
, ImmunoTox
#ImmunoOncology
, and
#PKU
programs. Every day we inch closer to what we hope will lead to a curable answer for human diseases.
For updates, get our Newsletter